sign free newsletters sign free newsletters trial failure raises doubts amyloid target drug development alzheimer disease beaten effort tame biogen japanese pharma partner eisai said thursday halting phase 3 clinical trials aducanumab drug designed slow worsening alzheimer known beta amyloid decision stop trials based interim analysis conducted independent monitoring committee analysis concluded aducanumab unlikely benefit alzheimer patients compared placebo trials completed biogen eisai said biogen eisai join long list drug companies tried successful treatments alzheimer failure aducanumab particularly discouraging supporters beta amyloid hypothesis accepted theory alzheimer disease destroys brain idea clumps debris containing protein called beta amyloid causing damage tested